Yarrow Bioscience Announces Participation in November Investor Events
Business Wire•02/11/2026•07:00 ET
0
Key Highlights
- ➤Yarrow executives will attend three healthcare investor conferences in November 2026
- ➤Guggenheim fireside chat scheduled for November 9 at 1:30 p.m. ET
- ➤YB-101 targets Graves’ disease and thyroid eye disease
- ➤Yarrow describes YB-101 as a potential first-in-class antibody
Yarrow Bioscience Announces Participation in November Investor Events
Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that members of its executive team will participate in the following upcoming investor conferences:
Get started
Create a free account to read the full story.